Aclarity Genomics files Form D for $4,625,000 equity offering

Aclarity Genomics, Inc., based in Morrisville, North Carolina, filed a Form D with the SEC disclosing an exempt securities offering. The company is incorporated in North Carolina and was formed within the last five years, in 2024.¹ Its industry classification is biotechnology, within the health care sector.¹

The offering claims exemption under Rule 506(b).¹ The filing lists a date of first sale of 2026-08-17.¹ The securities offered are equity, along with a security to be acquired upon exercise of an option, warrant, or other right to acquire a security.¹

The total offering amount and total amount sold are both listed as $4,625,000, with $0 remaining to be sold.¹ The filing states that 8 investors have already invested in the offering.¹ The form's investor section allows for a mix of accredited and non-accredited participants, and the filing does not specify how the eight investors break down between those categories.

The company reported $0 in sales commissions and finders' fees.¹ Proceeds are described as intended for working capital, which may include normal compensation to executive officers.¹

Shaun Lonergan is listed as an executive officer and director¹ alongside Jason West, also listed as an executive officer and director¹ of the company.

The notice was signed by Shaun Lonergan, identified as CEO, on 2026-09-02.¹ That signature date falls after the story date used for this report, a discrepancy that appears in the filing itself rather than in this account of it.